# Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)

> **NCT00724854** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1146 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepatitis C

## Interventions

- **BIOLOGICAL:** PegIntron (peginterferon alfa-2b; SCH 54031)
- **DRUG:** Rebetol (ribavirin; SCH 18908)

## Key facts

- **NCT ID:** NCT00724854
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 1146 (ACTUAL)
- **Last updated:** 2015-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724854, "Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00724854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*